Table of contents
- Trial types and study phases
- Melanoma studies
- Trials in BRAF-altered advanced cancers
- Hairy cell leukemia studies
- Studies in children with histiocytic disease
- Precision medicine and access studies
- Main outcomes measured in the trials
Trial types and study phases
All of the listed studies are interventional trials, which means the researchers give a treatment and then measure what happens.[1] Most of the trials are in Phase 2, a stage that usually checks how well a treatment works and continues to monitor safety.[1][2] Two studies are in Phase 3, which is a larger stage that often focuses more on safety and tolerability over a wider group of patients.[3][4]
Melanoma studies
One Phase 2 trial is studying Vemurafenib with cobimetinib and atezolizumab in people with high-risk, surgically resectable melanoma, including both BRAF-mutated and wild-type disease.[1] The main goal is to measure the pathologic complete response, which means no cancer is found in the removed tissue after treatment.[1]
This study is randomized and non-comparative, which means patients are assigned to treatment groups, but the study is not mainly designed to compare one group against another as a final proof of benefit.[1] It includes 94 patients and is authorised.[1]
Trials in BRAF-altered advanced cancers
One Phase 2 study looks at access to Vemurafenib for patients with metastatic or unresectable locally advanced malignancies that have BRAF genomic alterations.[2] These patients are described as no longer being amenable to curative treatment, meaning treatment is not expected to completely remove the cancer.[2]
The main outcome is anti-tumor activity, measured by confirmed objective response or remission, including complete or partial response depending on the tumor type and response rules used in the study.[2] The trial includes 50 patients and is designed to explore Vemurafenib as a single drug across multiple tumor cohorts.[2]
Hairy cell leukemia studies
Two Phase 2 studies focus on hairy cell leukemia, a blood cancer. One trial studies Vemurafenib plus rituximab as a chemotherapy-free option for people with newly diagnosed disease, compared with standard cladribine-based treatment.[3] Its main efficacy endpoint is complete remission at about 6 months, and its main safety endpoint is the number of patients with drug-related severe toxicity.[3]
The other hairy cell leukemia study tests step-wise combinations of Vemurafenib, cobimetinib, and obinutuzumab in patients who previously had purine analogs or who are not fit for chemotherapy.[4] Eligible patients include those with disease that did not respond well, came back early, had serious side effects from prior treatment, refused chemotherapy, or had active infection that makes chemotherapy risky.[4] The trial looks at response rates in several cohorts of patients with the BRAF-V600E mutation.[4]
Studies in children with histiocytic disease
One Phase 2 trial studies Vemurafenib in children with BRAF mutation-resistant histiocytic cell proliferation that did not respond to standard treatment.[5] The trial aims to check safety, effectiveness, and treatment duration, and it also tries to find a dose in children under 18 that gives drug exposure similar to adults.[5]
The primary outcome includes event-free survival, which means the time patients remain free from a defined event such as progression or failure of treatment.[5] Safety is also assessed with adverse event review, vital signs, lab tests, echocardiography, and ECG findings.[5]
Precision medicine and access studies
Several trials are part of broader precision medicine programs that match treatment to tumor biology. In the Finnish FINPROVE study, Vemurafenib is one of many targeted drugs offered to patients with advanced cancer, and the main endpoint is disease control at 16 weeks, defined as complete response, partial response, or stable disease.[6]
The Danish ProTarget study also includes Vemurafenib among targeted drugs for cancer guided by genomic profiling.[7] Its main outcomes are anti-tumor activity at 16 weeks, stable disease at 16 weeks, and treatment-related or serious adverse events.[7]
The DRUP trial is a very large Phase 2 study that includes patients with advanced solid tumors, non-Hodgkin lymphoma, T-cell prolymphocytic leukemia, and multiple myeloma.[8] It studies commercially available targeted drugs, including Vemurafenib, in patients whose tumors have a molecular feature that may predict benefit.[8]
Main outcomes measured in the trials
The trials use different endpoints, but many focus on response, which means how much the disease improves after treatment.[1][2][3][4]
- Pathologic complete response in melanoma: no residual cancer is found in the surgical specimen after treatment.[1]
- Confirmed objective response in advanced cancers: the study checks for complete or partial tumor shrinkage using formal response rules.[2]
- Complete remission in hairy cell leukemia: the disease appears to disappear by the study’s criteria.[3]
- Response rate in step-wise hairy cell leukemia cohorts: each group must reach a pre-set level of response for the treatment to be considered active.[4]
- Disease control at 16 weeks in precision medicine trials: complete response, partial response, or stable disease at the chosen time point.[6][7]
- Safety endpoints: many studies count serious adverse events, grade 3 or higher toxic effects, or treatment stops caused by side effects.[3][7][8]
Across these trials, Vemurafenib is being studied in people with very different diseases, but many of the studies share one idea: treatment is matched to a tumor feature, especially a BRAF alteration.[2][4][5][7][8]
